Economic Losses Associated with COVID-19 Deaths in the United States

Troy Quast, Ph.D.,^a Ross Andel, Ph.D.,^b Sean Gregory, Ph.D.,^{c,d} Eric A. Storch, Ph.D.^d

^aUniversity of South Florida, College of Public Health, Tampa, FL 33612

^bUniversity of South Florida, College of Behavioral and Community Sciences, Tampa, FL 33620;

Charles University and Motol University Hospital, Department of Neurology, Prague;

International Clinical Research Center, St. Anne's University Hospital, Brno

^cDepartment of Politics & International Affairs, Northern Arizona University, Flagstaff, AZ 86011

^dMenninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine,
Houston, TX 77030

Keywords: COVID-19; economic loss; years of life lost; United States

JEL codes: I12, I18, J17

Corresponding Author: Troy Quast (troyquast@usf.edu)

Abstract

In addition to the overwhelming health effects of COVID-19, the disease has inflicted unprecedented economic damage. Vast resources have been directed at COVID-19 testing and health care while economic activity has been substantially curtailed due to disruptions resulting from individual choices and government policies. This study estimates the economic loss associated with COVID-19 deaths in the U.S. from February 1, 2020 through July 11, 2020. We use estimates of years of life lost that are based on the age and gender of decedents. Using a value of life year estimate of \$66,759, we calculate economic losses of roughly \$66 billion. The losses are concentrated in New York and New Jersey, which account for 17.5% of the total losses. Our analysis of per capita losses by state indicates that the highest values are located in the northeastern region of the country, while the values in the western states are relatively low. While economic losses associated with COVID-19 deaths is just one aspect of the pandemic, our estimates can provide context to the value of prevention and mitigation efforts.

Introduction

While the health effects of COVID-19 are devastating, the economic effects of the pandemic are also profound. Estimates suggest that if 20% of the population were infected, the direct medical costs in the United States (U.S.) would be roughly \$163 billion (Bartsch et al, 2020). These costs include testing, ambulatory care, hospitalizations, and extended treatment of long-term effects of the disease. The economic costs also include the reduction and, in some cases, complete stoppage of economic activity due to government policies and individual behavior. These costs have been estimated to reduce real gross domestic product (GDP) growth by 5% per month (Makridis and Hartley, 2020).

Another important component of the economic costs of COVID-19 involves losses due to deaths from the disease. While the approaches are imperfect, economists have long attempted to estimate costs of deaths due to actual or potential policies and events. A common approach is employ value of a statistical life (VSL) estimates. Generally, the number of deaths is multiplied by the VSL to estimate the economic cost. This approach is used by U.S. government agencies (Robinson, 2007) and by researchers in areas such as transportation (Rizzi and Ortuzar, 2005; Dua, 2015), health interventions (Laxminarayan et al, 2014; Sproul et al, 2012; Scharff, 2012), and environmental studies (Franchini, 2015; Lee et al, 2011). While these analyses are informative, a significant drawback is that they do not explicitly account for the age profile of the decedents. For instance, under this approach the same value is assigned to a newborn as is assigned to a very sick individual near death.

This paper estimates the economic losses associated with the roughly 130,000 COVID-19 deaths in the U.S. from February 1, 2020 to July 11, 2020. Our approach employs years of lost life (YLL) estimates, which are based on the age and gender of the decedents, reported in Quast, et al (2020). We estimate the economic losses associated with COVID-19 deaths to be roughly \$66 billion.

Methods and Materials

Our general approach is to multiply the YLLs by an estimated value of each life year. This strategy has been used in studies of areas including health behaviors (Nonnemaker et al, 2014), pollution (Desaigues et al, 2011; Grandjean and Bellanger, 2017; Kim et al, 2020), and health outcomes (Temkin et al, 2019; Pezzullo, et al, 2018). Our YLL estimates are based on an analysis by Quast et al (2020) of data contained from the “Provisional COVID-19 Death Counts by Sex, Age, and State” published by the National Center for Health Statistics in the U.S. Centers for Disease Control and Prevention (CDC). These data separately report deaths for New York and New York City and do not contain data for Wyoming. Quast et al (2020)

merged the death counts with life expectancy estimates by age and gender obtained from actuarial life tables published by the U.S. Social Security Administration. For each age-gender group, the unadjusted YLL estimates were obtained by multiplying the number of individuals in that group by the difference in life expectancy and the age at death. The population-wide number of YLLs was found by summing across the age-gender groups.

As noted by Hanlon et al (2020), those who died of COVID-19 often had pre-existing morbidities which may have otherwise prevented them from reaching their life expectancy. The authors created a model of COVID-19 deaths in the United Kingdom that used data from Italy and found that, adjusting for pre-existing morbidities, the average estimated YLLs for men fell from 14 to 13 and for women from 12 to 11. Our primary specification follows Quast et al (2020) and reduces the life expectancy of decedents by 25% to reflect the typically lower pre-COVID-19 health status of those who died.

A value of life year (VOLY) estimate must be identified to calculate the economic cost associated with YLLs. We employ a value reported by Desaigues, et al (2011) that was based on a stated preferences approach. They asked residents of European Union countries their willingness to pay for policies that reduced pollution and, thus, increased life expectancy. Their estimate of 41,000 Euros has been employed in previous economic loss calculations (Temkin et al, 2019; Grandjean and Bellanger, 2017; Kim et al, 2020). The value converted to 2020 U.S. dollars is \$66,759. We also calculated economic losses using lower and upper benchmarks (\$100,000 and \$150,000) employed by the Institute of Clinical and Economic Review when conducting cost-effectiveness analyses (Institute for Clinical and Economic Review, 2017). However, these benchmark values are based on quality-adjusted life years and are not directly comparable to VOLY estimates. We discounted future dollar amounts by 3% per year.

To estimate per-capita values, we use population data from the “Annual State Resident Population Estimates” published by the U.S. Census Bureau as of July 1, 2019 and were obtained by gender. We obtained the population of New York City and the percentage of population by gender as of July 1, 2019 from “QuickFacts: New York City, New York” published by the U.S. Census Bureau.

Results

Table 1 details the economic losses using our primary VOLY estimate of \$66,759 and the two benchmark ICER values. The values are based on reducing the life expectancy estimates by 25%. Appendix Table 1 reports the values for our primary VOLY estimate and life expectancy reductions of 0% and 50%.

The total estimated losses associated with COVID-19 deaths in the U.S. during our analysis period were roughly \$66 billion. The losses were highly concentrated among the top states. New York City alone accounted for roughly 17.5% of the total losses while New York City, New Jersey, and New York state (excluding New York City) combined incurred over one-third of the total losses. The top ten jurisdictions accounted for roughly 70% of the total losses.

Figure 1 shows the economic loss per capita using our primary VOLY estimate and the 25% reduction in estimated life expectancy. (New York and New York City are combined in the map.) The largest values are concentrated in the northeastern section of the country, while the highest value outside of the region was in Louisiana. The western half of the country had lower per capita economic losses.

Discussion

The human toll of COVID-19 is devastating and takes precedence when considering the pandemic's effects. However, estimates of the economic loss can provide context in terms of the cost of prevention and mitigation efforts. Deaths are just one aspect of the toll of COVID-19, but are arguably the most important. We estimate the total economic loss due associated with COVID-19 deaths in the U.S. to be roughly \$66 billion which, if extrapolated to an annual basis, corresponds to roughly 0.7% of the U.S. GDP in 2019. We observe large absolute and per capita losses in the northeast region of the country while the western region of the country generally has lower per-capita losses.

As noted above, another potential approach to estimate economic losses due to deaths is to base the calculation on the VSL rather than on the projected number of years of life lost. VSLs are typically estimated via either stated or revealed preference for how much compensation an individual would demand to incur greater risk. Using a VSL of \$9.6 million (Viscusi, 2015; Viscusi and Masterman, 2017), the corresponding economic loss associated with the 130,088 deaths is roughly \$1.2 trillion, a value roughly eighteen times greater than our estimate. Economic loss estimates based on VOLYs and VSLs are not directly comparable, but the wide range of the two values suggest that adjusting for the relatively older age profile of COVID-19 decedents has a substantial effect on economic loss estimates.

Our analysis has several limitations. Most notably, we only estimate losses associated with deaths. Costs due to other aspects such as hospitalizations, long-term health effects, and reductions in economic activity need to be included in an estimate of the overall cost of COVID-19. Our reduction in projected life expectancy by 25% is an approximate value. However, we believe it is a conservative approach that reflects the current understanding of COVID-19 mortality risk. We used a single VOLY estimate for the

entire country which does not reflect potential variation in valuations across states. Further, if an estimate was available, it would be preferred to use an estimate based on surveys of U.S. rather than E.U. residents. Finally, our analysis period only represents the early stages of the COVID-19 outbreak in the U.S. As the virus ebbs and flows throughout the country and additional lives are lost, both the total economic loss but also the ranking of jurisdictions will change.

Compliance with Ethical Standards

The authors declare that they have no conflict of interest.

References

- Bartsch, S.M., et al. (2020). "The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States." *Health Affairs* 39, 927–935.
- Desaigues, B., et al. (2011). "Economic valuation of air pollution mortality: A 9-country contingent valuation survey of value of a life year (VOLY)." *Ecological Indicators* 11, 902–910.
- Dua, Anahita, et al. (2015). "National mandatory motorcycle helmet laws may save \$2.2 billion annually: An inpatient and value of statistical life analysis." *Journal of Trauma and Acute Care Surgery* 78(6), 1182–1186.
- Franchini, Massimo, et al. (2015). "The health and economic burden of air pollution." *The American Journal of Medicine* 128(9), 931–932.
- Grandjean, P., Bellanger, M. (2017). "Calculation of the disease burden associated with environmental chemical exposures: application of toxicological information in health economic estimation." *Environmental Health* 16, 123.
- Hanlon, P., et al. (2020). "COVID-19 – exploring the implications of long-term condition type and extent of multimorbidity on years of life lost: a modelling study." *Wellcome Open Research* 5, 75. Available at: <https://wellcomeopenresearch.org/articles/5-75/v1>.
- Institute for Clinical and Economic Review (2017). "Final Value Assessment Framework: Updates for 2017–2019." Available at: <https://icer-review.org/wp-content/uploads/2017/06/ICER-value-assessment-framework-Updated-050818.pdf>.
- Kim, S., et al. (2020). "Health and economic consequences of applying the United States' PM2.5 automobile emission standards to other nations: a case study of France and Italy." *Public Health* 183, 81–87.
- Laxminarayan, Ramanan, et al. "Valuing vaccines using value of statistical life measures." *Vaccine* 32(39), 5065–5070.
- Lee, Yong Jin, et al. (2011). "Evaluating the PM damage cost due to urban air pollution and vehicle emissions in Seoul, Korea." *Journal of Environmental Management* 92(3), 603–609.

Makridis, C., Hartley, J. (2020). "The Cost of Covid-19: A Rough Estimate of the 2020 US GDP Impact." *SSRN Journal*. Available at: <https://www.ssrn.com/abstract=3570731>.

Nonnemaker, J., et al. (2014). "Mortality and Economic Costs From Regular Cigar Use in the United States." *American Journal of Public Health*. 104, e86–e91.

Pezzullo, Lynne, et al. (2018) "The economic impact of sight loss and blindness in the UK adult population." *BMC Health Services Research*. 18(1), 63.

Quast, Troy, et al. (forthcoming). "Years of Life Lost Associated with COVID-19 Deaths in the United States." *Journal of Public Health*. Available at: <https://academic.oup.com/jpubhealth/advance-article/doi/10.1093/pubmed/fdaa159/5901977>

Rizzi, Luis, Ortuzar, Juan. (2003). "Stated preference in the valuation of interurban road safety." *Accident Analysis & Prevention* 35(1), 9-22.

Robinson, L.A. (2007). "How US Government Agencies Value Mortality Risk Reductions." *Review of Environmental and Economic Policy* 1, 283–299.

Scharff, Robert L. (2012). "Economic burden from health losses due to foodborne illness in the United States." *Journal of Food Protection* 75(1), 123-131.

Sproul, Thomas W., et al. (2012). "The cost of saving a statistical life: a case for influenza prevention and control." in *Health and Animal Agriculture in Developing Countries* 135-141. Springer, New York, NY,

Temkin, A., et al. (2019). "Exposure-based assessment and economic valuation of adverse birth outcomes and cancer risk due to nitrate in United States drinking water." *Environmental Research* 176, 108442.

U.S. Centers for Disease Control and Prevention (CDC). "Provisional COVID-19 Death Counts by Sex, Age, and State." Available at: <https://data.cdc.gov/NCHS/Provisional-COVID-19-Death-Counts-by-Sex-Age-and-S/9bhg-hcku>.

Viscusi, W. Kip (2015). "The role of publication selection bias in estimates of the value of a statistical life." *American Journal of Health Economics* 1(1), 27-52.

Viscusi, W.K., Masterman, C.J. (2017). "Income Elasticities and Global Values of a Statistical Life." *Journal of Benefit-Cost Analysis* 8, 226–250.

Table 1. Economic losses (\$000s) by jurisdiction based on various VOLY estimates.

Jurisdiction	VOLY estimate		
	\$66,759	\$100,000	\$150,000
US Total	65,824,441	98,600,100	147,900,150
New York City	11,600,711	17,377,000	26,065,500
New Jersey	6,971,909	10,443,400	15,665,100
New York (excl NYC)	5,467,362	8,189,700	12,284,550
California	3,790,242	5,677,500	8,516,250
Illinois	3,506,650	5,252,700	7,879,050
Pennsylvania	3,159,436	4,732,600	7,098,900
Massachusetts	3,106,296	4,653,000	6,979,500
Michigan	2,921,841	4,376,700	6,565,050
Texas	2,206,318	3,304,900	4,957,350
Florida	2,128,410	3,188,200	4,782,300
Maryland	1,848,957	2,769,600	4,154,400
Louisiana	1,664,569	2,493,400	3,740,100
Connecticut	1,692,207	2,534,800	3,802,200
Arizona	1,376,370	2,061,700	3,092,550
Georgia	1,381,978	2,070,100	3,105,150
Indiana	1,268,421	1,900,000	2,850,000
Ohio	1,237,912	1,854,300	2,781,450
Virginia	983,160	1,472,700	2,209,050
Colorado	766,660	1,148,400	1,722,600
Alabama	707,378	1,059,600	1,589,400
Mississippi	691,156	1,035,300	1,552,950
North Carolina	615,919	922,600	1,383,900
Minnesota	615,651	922,200	1,383,300
Washington	580,737	869,900	1,304,850
South Carolina	514,712	771,000	1,156,500
Missouri	467,046	699,600	1,049,400
Wisconsin	424,788	636,300	954,450
District of Columbia	389,071	582,800	874,200
Iowa	395,547	592,500	888,750
Tennessee	375,586	562,600	843,900
Rhode Island	383,530	574,500	861,750
Nevada	331,859	497,100	745,650
New Mexico	300,816	450,600	675,900
Kentucky	311,097	466,000	699,000
Delaware	245,940	368,400	552,600
Oklahoma	208,622	312,500	468,750
Arkansas	198,675	297,600	446,400
Nebraska	156,884	235,000	352,500
Kansas	157,551	236,000	354,000
New Hampshire	145,601	218,100	327,150
Utah	124,706	186,800	280,200
Oregon	124,038	185,800	278,700
South Dakota	55,877	83,700	125,550
Maine	53,073	79,500	119,250
North Dakota	45,797	68,600	102,900
Idaho	46,331	69,400	104,100
West Virginia	43,994	65,900	98,850
Vermont	22,231	33,300	49,950
Montana	10,815	16,200	24,300

Figure 1. Economic loss (\$) per capita by jurisdiction.

Appendix Table 1. Economic losses (\$000s) by jurisdiction based on various adjustments to life expectancy.

Jurisdiction	Reduction in life expectancy		
	0%	25%	50%
US Total	82,794,044	65,824,441	46,658,933
New York City	14,521,418	11,600,711	8,264,564
New Jersey	8,766,191	6,971,909	4,943,905
New York (excl NYC)	6,891,131	5,467,362	3,866,748
California	4,748,701	3,790,242	2,698,265
Illinois	4,398,751	3,506,650	2,493,048
Pennsylvania	4,005,540	3,159,436	2,220,404
Massachusetts	3,956,539	3,106,296	2,172,271
Michigan	3,672,546	2,921,841	2,072,466
Texas	2,750,404	2,206,318	1,579,117
Florida	2,680,174	2,128,410	1,507,084
Maryland	2,322,546	1,848,957	1,312,615
Connecticut	2,150,841	1,692,207	1,185,974
Louisiana	2,088,088	1,664,569	1,183,370
Georgia	1,733,064	1,381,978	982,692
Arizona	1,718,310	1,376,370	983,827
Indiana	1,605,287	1,268,421	893,035
Ohio	1,567,835	1,237,912	870,804
Virginia	1,241,584	983,160	693,826
Colorado	968,339	766,660	541,015
Alabama	886,359	707,378	503,430
Mississippi	863,928	691,156	493,215
Minnesota	782,883	615,651	431,263
North Carolina	774,872	615,919	436,537
Washington	733,281	580,737	409,900
South Carolina	647,562	514,712	364,571
Missouri	590,951	467,046	328,922
Wisconsin	533,805	424,788	301,417
Iowa	498,022	395,547	280,054
Rhode Island	488,476	383,530	268,171
District of Columbia	485,471	389,071	278,118
Tennessee	470,584	375,586	267,303
Nevada	415,508	331,859	236,327
Kentucky	393,010	311,097	219,504
New Mexico	373,383	300,816	216,499
Delaware	310,162	245,940	173,840
Oklahoma	263,297	208,622	147,270
Arkansas	248,210	198,675	141,863
Kansas	198,074	157,551	111,688
Nebraska	196,672	156,884	111,554
New Hampshire	186,057	145,601	101,407
Oregon	156,550	124,038	87,521
Utah	156,216	124,706	88,789
South Dakota	70,498	55,877	39,455
Maine	67,560	53,073	37,118
Idaho	59,282	46,331	32,245
North Dakota	57,947	45,797	32,178
West Virginia	56,011	43,994	30,709
Vermont	28,373	22,231	15,488
Montana	13,752	10,815	7,544